Frank Bühling

4.1k citations
82 papers · 3.3k indexed · h-index 35
Topics
Peptidase Inhibition and Analysis (24 papers)Protease and Inhibitor Mechanisms (22 papers)Neuropeptides and Animal Physiology (13 papers)

In The Last Decade

Frank Bühling

80 papers receiving 3.2k citations

Peers

Frank Bühling
Comparison fields: 5 of 116
  • Molecular Biology 1.3k
  • Oncology 860
  • Pulmonary and Respiratory Medicine 712
  • Cancer Research 558
  • Immunology 523
Replace Su-Ming Hsu with:
Su-Ming Hsu United States
Yoshinobu Eishi Japan
Isao Kitajima Japan
Dirk Reinhold Germany
Atsushi Tamura Japan
Masayuki Ando Japan
Cory Brayton United States
Kazuo Motoyoshi Japan
Linda K. Johnson United States
Ludger Fink Germany
Frank Bühling relative to Su-Ming Hsu United States Su-Ming Hsu's profile →
Citations per field
00.5×
Su-Ming Hsu · 1×
Citations per year

Countries citing papers authored by Frank Bühling

Since Specialization
Citations

This map shows the geographic impact of Frank Bühling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Bühling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Bühling more than expected).

Fields of papers citing papers by Frank Bühling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Bühling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Bühling. The network helps show where Frank Bühling may publish in the future.

Co-authorship network of co-authors of Frank Bühling

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Bühling. A scholar is included among the top collaborators of Frank Bühling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Bühling. Frank Bühling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 5
2 24
3 46
4 27
5 115
6 0
7 72
8 61
9 33
10 21
11 68
12 41
13 29
14 4
15 4
16 55
17 25
18 23
19 53
20 40

About Frank Bühling

Frank Bühling is a scholar working on Cancer Research, Oncology and Cellular and Molecular Neuroscience, having authored 82 papers that have together received 3.3k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (24 papers), Protease and Inhibitor Mechanisms (22 papers) and Neuropeptides and Animal Physiology (13 papers). The work is most often cited by research in Cancer Research (558 citations), Oncology (860 citations) and Immunology (523 citations). Frank Bühling has collaborated with scholars based in Germany, United States and Croatia. Frequent co-authors include Tobias Welte, Caroline E. Chwieralski, Dirk Reinhold, Siegfried Ansorge, S Ansorge, Christoph Röcken, Dieter Brömme, Ute Bank, Annegret Gerber and Frank Brasch. Their work appears in journals such as Journal of Biological Chemistry, The Journal of Immunology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026